Treatment with continuous subcutaneous insulin infusion (CSII) in children with type 1 Diabetes (DM1) may lead to changes in glucose monitoring data and health-related quality of life (HRQOL).
A study was designed to assess differences in glucose monitoring data and HRQOL according to HbA1c as indicator of glycemic control.
Glycemic metrics were recorded from glucose monitoring devices of 157 children aged 8 to 18, treated with CSII or multiple dose injection (MDI) in 8 Pediatrics Diabetes Units in Spain. These patients filled up DCGM-12 as HRQOL instrument. The patients were divided in three groups: patients with CSII and Hb1c < 7.5%, patients with CSII and HbA1c ≥ 7.5%, and patients with MDI.
| Insulin pumps | MDI (n:103) | Statistical significance | ||
| HbA1c < 7.5% (n:40) | HbA1c ≥ 7.5% (n:14) | |||
| Χ ± SD | ||||
| Time in range: 70-180 mg/dl (%) | 62.51 ± 9.46 | 50.08 ± 15.16 | 57.37 ± 18.15 | 0.038 |
| Hyperglycemia > 180 mg/dl (%) | 31.37 ± 12.82 | 46.94 ± 19.51 | 39.72 ± 22.83 | 0.025 |
| Hypoglycemia < 70 mg/dl (%) | 8.05 ± 5.62 | 4.11 ± 4.98 | 6.54 ± 8.03 | 0.203 |
| DCGM-12. Range (0-100) | 81.46 ± 12.50 | 88.84 ± 8.75 | 79.81 ± 14.50 | 0.068 |
The patients treated with CSII whose HbA1c was less than 7.5% had bigger percentage of time in range and less time in hyperglycemia than the group with worse glycemic control.
Both groups of patients with CSII had bigger HRQOL than the patients treated with MDI but the group with CSII and better glycemic control had worse HRQOL than the other CSII group.